Dataset Information


Cardiac gene expression profiling of apoE-deficient mice receiving heart failure treatment with the anti-ischemic drug ranolazine

ABSTRACT: Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We used 18 month-old apolipoprotein E (apoE)- deficient mice as a model of atherosclerosis-induced heart failure to analyze whether the anti-ischemic drug ranolazine could retard the progression of heart failure. The study showed that 2 months of ranolazine treatment improved cardiac function of 18 month-old apoE-deficient mice with symptoms of heart failure as assessed by echocardiography. To identify changes in cardiac gene expression induced by treatment with ranolazine a microarray study was performed with heart tissue from failing hearts relative to ranolazine-treated and healthy control hearts. The microarray approach identified heart failure-specific genes that were normalized during treatment with the anti-ischemic drug ranolazine. Microarray gene expression profiling was performed with heart tissue isolated from (i) untreated 18 month-old apoE-deficient mice with heart failure relative to (ii) 18 month-old apoE-deficient mice treated for two months with the anti-ischemic drug ranolazine (200 mg/kg), and (iii) age-matched non-transgenic C57BL/6J (B6) control mice.

ORGANISM(S): Mus musculus  

SUBMITTER: Ursula Quitterer   Said AbdAlla 

PROVIDER: E-GEOD-25767 | ArrayExpress | 2010-12-03



Similar Datasets

2010-12-03 | E-GEOD-25765 | ArrayExpress
2010-12-03 | E-GEOD-25768 | ArrayExpress
2011-03-18 | E-GEOD-28031 | ArrayExpress
2012-12-11 | E-GEOD-42813 | ArrayExpress
2010-12-03 | E-GEOD-25766 | ArrayExpress
2009-12-14 | E-GEOD-19286 | ArrayExpress
2015-01-01 | E-GEOD-53548 | ArrayExpress
2015-08-21 | E-GEOD-72248 | ArrayExpress
2013-07-31 | E-GEOD-49351 | ArrayExpress
2012-12-06 | E-GEOD-42753 | ArrayExpress